Childhood-juvenile multiple sclerosis: Clinical characteristics and treatment

Expert Review of Neurotherapeutics

Volumn 5, Issue 3, 2005, Pages 403-411

  Ghezzi, Angelo ^a  

^a Ospedale di Gallarate   (Italy)

Author keywords

Acute disseminated encephalomyelitis; Adolescence; Cerebrospinal fluid; Childhood; Diagnosis; Glatiramer acetate; Immunomodulatory drugs; Interferon ; Magnetic resonance imaging; Multiple sclerosis; Prognosis

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

ADOLESCENT; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISABILITY; DRUG MEGADOSE; DRUG PULSE THERAPY; ENCEPHALOMYELITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GENDER; HEADACHE; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; LEUKOPENIA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RELAPSE; REVIEW; THORAX PAIN; THROMBOCYTOPENIA;

AGE FACTORS; AGE OF ONSET; CHILD; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; SEX FACTORS;

EID: 18944396007     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.3.403     Document Type: Review

References (43)

1. Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). Excellent review of recent insight into multiple sclerosis (MS).
2. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001).
3. Trapp B, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295-302 (1999).
4. Confavreux C, Vokusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770-782 (2003).
5. Duquette P, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediatrics 111, 359-363 (1987).
6. Ghezzi A, Deplano V, Faroni J et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult. Scler. 3, 43-46 (1997).
7. Ghezzi A, Pozzilli C, Liguori M et al. Prospective study of multiple sclerosis with early onset. Mult. Scler. 8, 115-118 (2002).
8. Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early onset MS. Comparison with adult-onset forms. Neurology 59, 1922-1928 (2002).
9. Boiko A, Vorobeychik G, Paty D et al. Early onset multiple sclerosis. A longitudinal study. Neurology 59, 1006-1010 (2002).
10. Gusev E, Boiko A, Bikova O et al. The natural history of early onset multiple sclerosis: comparison of data from Moskow and Vancouver. Clin. Neurol. Neurosurg. 104, 203-207 (2002).
11. Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol. Sci. 25, S366-S369 (2004). Summary of clinical data from studies up to 2004 on MS with onset during childhood or adolescence.
12. Mikaeloff Y, Suissa S, Vallee et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 144, 246-252 (2004). Important study evaluating prognostic factors for second attack and for disability after an initial episode of CNS demyelination in children.
13. Ruggieri M, Iannetti P, Polizzi A et al. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 25, S326-S335 (2004). Complete review of clinical and laboratory characteristics of MS in subjects under 10 years of age.
14. Pinhas-Hamiel O, Sarova-Pinhas I, Achiron A. Multiple sclerosis in childhood and adolescence. Clinical features and management. Paediatr. Drugs 3, 329-336 (2001).
15. Ruggieri M, Polizzi A, Pavone L, Grimaldi ME. Multiple sclerosis in children under 6 years of age. Neurology 53, 478-484 (1999).
16. Hanefeld F, Bauer HJ, Christen H et al. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 13, 410-416 (1991).
17. Duquette P, Girard M. Hormonal factors in susceptibility to multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 6, 195-201 (1993).
18. Tardieu M, Mikaeloff Y. Multiple sclerosis in children. Int. Multiple Sclerosis J. 11, 36-42 (2004).
19. Dale RC, de Sousa C, Chong WK, Cox TCS, Harding B, Neville BGR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123, 2407-2422 (2000).
20. Brass SD, Caramanos Z, Santos C et al. Multiple Sclerosis vs. acute disseminated encephalomyelitis in childhood. Pediatr. Neurol. 29, 227-231 (2003).
21. Mikaeloff Y, Adamsbaun C, Husson B et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 127, 1942-1947 (2004). Analysis and comparison of the characteristics of magnetic resonance imaging (MRI) in children with MS with MRI criteria commonly used in adults with MS in predicting the risk of conversion to clinically definite MS.
22. Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis. Neurology 62, 806-808 (2004). Describes cerebrospinal fluid characteristics of a cohort of 136 patients with onset before the age of 16, discussing the role of oligoclonal bands for diagnosis of MS versus acute disseminating encephalomyelitis.
23. Fazekas F, Offenbacher H, Fuchs S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38, 1822-1825 (1988).
24. Paty DW, Oger JJ, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and computed tomography (CT). Neurology 38, 180-185 (1988).
25. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120, 2059-2069 (1997).
26. Mezzapesa D, Rocca MA, Falini A et al. A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis. Arch. Neurol. 61, 366-368 (2004). Nonconventional MRI techniques have been used in this study, demonstrating that, differently from the adult form, the normal appearing brain tissue is spared in early-onset MS.
27. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 63, 1966-1967 (2004).
28. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis. Neurology 58 (N2), 169-178 (2002).
29. Barnes D, Hughes RA, Morris RW et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349, 902-906 (1997).
30. Morrow SA, Stoian CA, Dmitrovic J et al. The bioavailability of intravenous methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63, 1079-1080 (2004).
31. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology, 49, 1404-1413 (1997).
32. Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing remitting MS. Neurology 57, 1239-1247 (2001).
33. 1b and childhood multiple sclerosis. Pediatr. Neurol. 21, 481-483 (1999).
34. Tenenbaun S, Martin S, Fejeman N. Disease-modifying therapies in childhood juvenile multiple sclerosis. Mult. Scler. 7(Suppl.1), S57 (2001).
35. Tenenbaun SN, Segura MJ. Clinical effects of disease-modifying therapies in early-onset multiple sclerosis. Neurology P06, 080 (2004).
36. Mikaeloff Y, Moreau T, Debouverie M et al. Interferon-β treatment in patients with child-onset multiple sclerosis. J. Pediatr. 139, 443-446 (2001).
37. Moiola L. Efficacy and tolerability of immunomodulatory treatments in children with multiple sclerosis. Mult. Scler. P158 (2003).
38. Kornek B, Bernert G, Balassy C et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34, 120-126 (2003).
39. 1a (Rebif®) in children and adolescents with multiple sclerosis. Mult. Scler. P610 (2004).
40. Ghezzi A, Gallo P, Marrosu MG et al. Effectiveness and tolerability of immunomodulatory drugs in multiple sclerosis during childhood or adolescence. Neurology 62, P06-P078 (2004).
41. Ghezzi A, Amato MP, Gallo P et al. Disease modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult. Scler. P554 (2004).
42. Ghezzi A, Ruggieri M, Trojano M, Filippi M and the ITEMS study. Italian studies on early-onset multiple sclerosis: the present and the future. Neurol. Sci. 25, S346-S349 (1997).
43. Takahashi I, Sawaishi Y, Takeda O et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr. Neurol. 17, 83-87 (1997).